Please assess the completion status of the following clinical trial:

Trial Title: Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Main Inclusion Criteria:~* Participants with clinical diagnosis of moderate to severe acne vulgaris on the face defined by:~  1. Investigator's Global Assessment score of 3 or 4, with same score on both sides; and~ 2. A minimum of 25 inflammatory lesions (papules and pustules) in total, with at least 10 on each side (excluding the nose); and~ 3. No more than two acne nodules (less than or equal to \[\>=\] 1 centimeter \[cm\]); and~ 4. A minimum of 10 atrophic acne scars in total (upper than 2 millimeters \[mm\]) (excluding the nose)~* Participants with a symmetric number of both inflammatory and non-inflammatory lesions on the whole face, and atrophic acne scars on the whole face.~* Participants with skin phototype of I to IV on Fitzpatrick's scale.~Main Exclusion Criteria:~* Participants with acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne, etc.), nodulo cystic acne, acne requiring systemic treatment.~* Prior failure to treatment with TactuPump® Forte (Adapalene 0.3% - BPO 2.5%).~* Participants with more than 3 excoriated acne lesions.~* Participants with skin abraded on the treated area or affected by eczema, seborrhoeic dermatitis, cuts or sunburn.~* Female participant who is pregnant, nursing or planning a pregnancy during the trial or within one month after the last trial treatment application.~* Male participant with a beard or facial hair, which would interfere with the clinical trial evaluations or clinical trial procedures.~* Participants having received at least one of the following topical treatments on the treated area: Corticosteroids, antibiotics, benzoyl peroxide, azelaic acid, hydroxyacids, Zinc containing treatments, antibacterials, antiseptics, other anti-inflammatory drugs or other acne treatments (2 weeks); Retinoids (4 weeks); Cosmetic/aesthetic procedures on the face (1 week); Photodynamic therapy, laser therapy, microdermabrasion for acne (3 months).~* Participants having received at least one of the following systemic treatments: Corticosteroids (except locally acting corticosteroids such as inhaled or intrathecal or dermal application at distance from the face), antibiotics (except penicillin) (1 month); Spironolactone (3 months) / Drospirenone (3 months, unless dose is stable since at least 3 months); Oral retinoids (6 months); Cyproterone acetate / Chlormadinone acetate (6 months); Immunomodulators (3 months).

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: ABPO Forte Gel (Type: EXPERIMENTAL): None
- Part 1: ABPO Forte Vehicle Gel (Type: PLACEBO_COMPARATOR): None
- Part 2: ABPO Forte Gel (Type: EXPERIMENTAL): None
- Part 2: ABPO Forte Vehicle Gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).